Adverse Effect
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Adverse Effect is a moderately active landscape with 42 programs across 20 companies. The most active players are Vitae Pharmaceuticals Inc., an Allergan affiliate, Hikma Pharmaceuticals LLC, Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. 13 therapies are approved with 1 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Analysis
Modality Breakdown
95%
Small molecule
42 of 44 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 44 classified programs, each share of the total. Modality classified for 100% of 48 pipeline programs.
Analysis
Trial Status
32
clinical trials
Clinical Trials
Trial Activity
32 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)